RT Journal Article
SR Electronic
T1 DEFINING CANDIDATE PARKINSON’S DISEASE GENES THROUGH THE ANALYSIS OF GENOME-WIDE HOMOZYGOSITY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.23.20235671
DO 10.1101/2020.11.23.20235671
A1 Lubbe, Steven J
A1 Wong, Yvette C.
A1 Bustos, Bernabe
A1 Kim, Soojin
A1 Vandrovcova, Jana
A1 Norman, Brendan P
A1 Tan, Manuela
A1 Murphy, David
A1 Carroll, Camille B
A1 Grosset, Donald
A1 Ryten, Mina
A1 Botía, Juan A.
A1 Escott-Price, Valentina
A1 Williams, Nigel M
A1 Krainc, Dimitri
A1 Morris, Huw R
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/25/2020.11.23.20235671.abstract
AB Early-onset Parkinson’s disease (EOPD) can be caused by biallelic mutations in PRKN, DJ1 and PINK1. However, while the identification of novel genes is becoming increasingly challenging, new insights into EOPD genetics have important relevance for understanding the pathways driving disease pathogenesis. Here, using extended runs of homozygosity (ROH) >8Mb as a marker for possible autosomal recessive inheritance, we identified 90 EOPD patients with extended ROH. Investigating rare, damaging homozygous variants to identify candidate genes for EOPD, 81 genes were prioritised. Through the assessment of biallelic (homozygous and compound heterozygous) variant frequencies in cases and controls from three independent cohorts totalling 3,381 PD patients and 2,463 controls, we identified two biallelic MIEF1 variant carriers among EOPD patients. We further investigated the role of disease-associated variants in MIEF1 which encodes for MID51, an outer mitochondrial membrane protein, and found that putative EOPD-associated variants in MID51 preferentially disrupted its oligomerization state. These findings provide further support for the role of mitochondrial dysfunction in the development of PD. Together, we have used genome-wide homozygosity mapping to identify potential EOPD genes, and future studies incorporating expanded datasets and further functional analyses will help to determine their roles in disease aetiology.Competing Interest StatementD.K. is the Founder and Scientific Advisory Board Chair of Lysosomal Therapeutics Inc. D.K. serves on the scientific advisory boards of The Silverstein Foundation, Intellia Therapeutics, and Prevail Therapeutics and is a Venture Partner at OrbiMed. All other authors declare that they do not have conflict of interests. H.R.M reports grants from Medical Research Council UK, grants from Wellcome Trust, grants from Parkinson's UK, grants from Ipsen Fund, during the conduct of the study; grants from Motor Neuron Disease Association, grants from Welsh Assembly Government, personal fees from Teva, personal fees from Abbvie, personal fees from Teva, personal fees from UCB, personal fees from Boerhinger-Ingelheim, personal fees from GSK, outside the submitted work.Funding StatementD.K. is supported by the Simpson Querrey Center for Neurogenetics. Please https://pdgenetics.org/partners for details regarding funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data access was granted through membership of the International Parkinson's disease Genetics Consortium, the PROBAND/Tracking Parkinson's project, or Parkinson's families project (REC 15/LO/0097), or following application through the relevant bodies (AMP-PD). The respective local ethical committees for medical research approved involvement in genetic studies and all participants gave written informed consent for the datasets top be used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used is available through application from the following sites: IPDGC: https://pdgenetics.org/contact AMP-PD: https://amp-pd.org